Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adlai Nortye Doses First Patient in Phase 1b Clinical Trial of AN0025 in Combination with Merck's KEYTRUDA for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00aePartner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Xiamen Biotime Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Nucleai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$106.1 million","upfrontCash":"Undisclosed","newsHeadline":"Adlai Nortye Ltd. Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$57.5 million","upfrontCash":"Undisclosed","newsHeadline":"Adlai Nortye Ltd. Announces Closing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Adlai Nortye

    Menu

    Adlai Nortye

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Adlai Nortye

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurr...

              Details:

              AN2025 (buparlisib ) is an oral pan-PI3K inhibitor, It is being evaluated in combination with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.

              Lead Product(s): Buparlisib,Paclitaxel

              Therapeutic Area: Oncology Product Name: AN2025

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adlai Nortye

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adlai Nortye Ltd. Announces Closing of Initial Public Offering

              Details:

              The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved, of AN2025.

              Lead Product(s): Buparlisib,Paclitaxel

              Therapeutic Area: Oncology Product Name: AN2025

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.

              Deal Size: $57.5 million Upfront Cash: Undisclosed

              Deal Type: Public Offering October 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adlai Nortye

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

              Details:

              The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved, of AN2025.

              Lead Product(s): Buparlisib,Paclitaxel

              Therapeutic Area: Oncology Product Name: AN2025

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.

              Deal Size: $106.1 million Upfront Cash: Undisclosed

              Deal Type: Public Offering September 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adlai Nortye

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trials

              Details:

              The collaboration aims to focus on identifying subjects that could derive benefit from AN2025 (buparlisib) treatment in metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) patients and will expand to other indications and clinical trials.

              Lead Product(s): Buparlisib,Paclitaxel

              Therapeutic Area: Oncology Product Name: AN2025

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Nucleai

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adlai Nortye

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort

              Details:

              In IND-213, HR+/HER2- breast cancer patients treated with Reolysin (pelareorep) and paclitaxel showed a statistically significant, near doubling of overall survival compared to those treated with paclitaxel alone.

              Lead Product(s): Pelareorep,Paclitaxel,Avelumab

              Therapeutic Area: Oncology Product Name: Reolysin

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Oncolytics Biotech

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adlai Nortye

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)

              Details:

              This includes the rights and interests of Adlai Nortye in the development, manufacturing and commercialization of AN4005 and AN3025 in Greater China, and AN1005, AN6015 and AN9015 worldwide.

              Lead Product(s): AN4005

              Therapeutic Area: Oncology Product Name: AN4005

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Xiamen Biotime Biotechnology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adlai Nortye

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

              Details:

              BRACELET-1, is ongoing and evaluates pelareorep-paclitaxel combination therapy both with and without a checkpoint inhibitor used in Chinese patients with advanced or metastatic breast cancer.

              Lead Product(s): Pelareorep,Paclitaxel

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Oncolytics Biotech

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adlai Nortye

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adlai Nortye Doses First Patient in Phase 1b Clinical Trial of AN0025 in Combination with Merck's KEYTRUDA for Advanced Solid Tumors

              Details:

              First patient has been dosed in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025, an investigational, potentially first in class oral EP4 antagonist, in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with locally advanced/metastatic solid tumors.

              Lead Product(s): AN0025,Pembrolizumab

              Therapeutic Area: Oncology Product Name: AN0025

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY